Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual.
Immunology
Structural biology
Virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
20 Oct 2023
20 Oct 2023
Historique:
received:
08
02
2023
revised:
10
07
2023
accepted:
18
09
2023
medline:
16
10
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has remained a medical threat due to the evolution of multiple variants that acquire resistance to vaccines and prior infection. Therefore, it is imperative to discover monoclonal antibodies (mAbs) that neutralize a broad range of SARS-CoV-2 variants. A stabilized spike glycoprotein was used to enrich antigen-specific B cells from an individual with a primary Gamma variant infection. Five mAbs selected from those B cells showed considerable neutralizing potency against multiple variants, with COVA309-35 being the most potent against the autologous virus, as well as Omicron BA.1 and BA.2, and COVA309-22 having binding and neutralization activity against Omicron BA.4/5, BQ.1.1, and XBB.1. When combining the COVA309 mAbs as cocktails or bispecific antibodies, the breadth and potency were improved. In addition, the mechanism of cross-neutralization of the COVA309 mAbs was elucidated by structural analysis. Altogether these data indicate that a Gamma-infected individual can develop broadly neutralizing antibodies.
Identifiants
pubmed: 37841584
doi: 10.1016/j.isci.2023.108009
pii: S2589-0042(23)02086-2
pmc: PMC10570122
doi:
Types de publication
Journal Article
Langues
eng
Pagination
108009Subventions
Organisme : Bill & Melinda Gates Foundation
ID : INV-004923
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM133894
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Science. 2021 Aug 13;373(6556):818-823
pubmed: 34016740
Sci Transl Med. 2022 Mar 23;14(637):eabi9215
pubmed: 35133175
JAMA. 2022 Sep 20;328(11):1104-1107
pubmed: 35913747
Biochem Biophys Res Commun. 2021 Jan 29;538:192-203
pubmed: 33069360
Nature. 2019 Feb;566(7744):393-397
pubmed: 30664748
J Struct Biol. 2012 Dec;180(3):519-30
pubmed: 23000701
Cell. 2020 Sep 17;182(6):1663-1673
pubmed: 32946786
Nat Commun. 2021 Jul 9;12(1):4210
pubmed: 34244522
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
Lancet Infect Dis. 2022 Jul;22(7):942-943
pubmed: 35690075
Nat Commun. 2021 Jun 21;12(1):3815
pubmed: 34155209
Cell. 2021 Aug 5;184(16):4203-4219.e32
pubmed: 34242577
Nat Med. 2020 Sep;26(9):1422-1427
pubmed: 32651581
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Front Immunol. 2020 Dec 15;11:605170
pubmed: 33384691
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Nat Protoc. 2014 Oct;9(10):2450-63
pubmed: 25255089
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nat Commun. 2020 Oct 27;11(1):5413
pubmed: 33110068
N Engl J Med. 2022 Apr 14;386(15):1477-1479
pubmed: 35263515
J Struct Biol. 2009 May;166(2):205-13
pubmed: 19374019
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nat Commun. 2022 Aug 4;13(1):4539
pubmed: 35927266
Sci Adv. 2021 Sep 03;7(36):eabj5365
pubmed: 34516917
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
Cell. 2020 Nov 12;183(4):1058-1069.e19
pubmed: 33058755
Cell Host Microbe. 2021 May 12;29(5):819-833.e7
pubmed: 33789084
Proc Natl Acad Sci U S A. 2022 May 17;119(20):e2120976119
pubmed: 35549549
Science. 2011 Aug 12;333(6044):843-50
pubmed: 21737702
J Med Virol. 2022 Apr;94(4):1738-1744
pubmed: 34905235
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
Immunity. 2020 Dec 15;53(6):1272-1280.e5
pubmed: 33242394
PLoS Med. 2022 May 17;19(5):e1003991
pubmed: 35580156
Immunity. 2022 Jun 14;55(6):1105-1117.e4
pubmed: 35397794
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Nat Struct Mol Biol. 2020 Oct;27(10):950-958
pubmed: 32737466
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Cold Spring Harb Protoc. 2011 Jun 01;2011(6):695-715
pubmed: 21632778
Sci Transl Med. 2021 Jan 27;13(578):
pubmed: 33397677
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Nat Med. 2022 Mar;28(3):490-495
pubmed: 35046573
Cell Discov. 2023 Jun 27;9(1):64
pubmed: 37369648
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
J Struct Biol. 2005 Jul;151(1):41-60
pubmed: 15890530
Commun Biol. 2022 Jul 29;5(1):766
pubmed: 35906394
Immunity. 2020 Jul 14;53(1):98-105.e5
pubmed: 32561270
iScience. 2023 Apr 21;26(4):106540
pubmed: 37063468
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Nat Commun. 2021 Oct 20;12(1):6097
pubmed: 34671037
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Bioinformatics. 2021 May 5;37(5):734-735
pubmed: 32805021
Immunity. 2022 Sep 13;55(9):1725-1731.e4
pubmed: 35973428
Science. 2022 Feb 18;375(6582):782-787
pubmed: 35076281
Brief Bioinform. 2021 Nov 5;22(6):
pubmed: 34015809